Possibility of RFK at HHS Sinks Ai-focused Drug Discovery Stocks

Introduction

Robert F. Kennedy Jr. being picked by President-elect Trump to head of the Department of Health & Human Services  hit the 6 stocks in the MunAiMarkets Ai-focused micro/small-cap clinical-stage drug discovery stocks portfolio hard last week with NO constituents advancing. Below are the details:

AI-Focused Drug Discovery Stocks Portfolio: DOWN 9.6% w/e November 15th

• +/- 10%:
  • Schrödinger (SDGR): -1.1%;
    • Area of Focus: uses its platform to discover novel molecules which it leverages to build a pipeline of its own clinical programs in addition to selling access to its platform to other pharmaceutical firms (see details here)
    • Market Capitalization: $1,350M
    • Pipeline: (see here)
  • AbCellera Biologics (ABCL): -1.9%
    • Area of Focus: searches for antibodies from natural immune responses which are then outsourced to their partners. (see details here)
    • Market Capitalization: $781M
    • Pipeline: (see here)
• <10-15%:
  • Recursion Pharmaceuticals (RXRX): – 13.0%
    • Area of Focus: decodes biology by integrating technological innovations to industrialize drug discovery (see details here)
    • Market Capitalization: $1,770M
    • Pipeline: (see here)
      • Recursion Pharmaceuticals Reports Q3 Loss, Misses Revenue Estimates 
  • Exscientia (EXAI): -13.8%
    • Area of Focus: designs and develops differentiated medicines for diseases with high unmet patient needs (see details here)
    • Market Capitalization: $614M
    • Pipeline: (see here)
• <15-20%:
  • Relay Therapeutics (RLAY): -17.6%
    • Area of Focus: uses its platform to enhance small molecule therapeutic discovery in targeted oncology and genetic disease indications (see details here)
    • Market Capitalization: $854M
    • Pipeline: (see here)
      • Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
•  < 20%:
  • Absci Corporation (ABSI): -30.2%
    • Area of Focus: analyzes drug characteristics that may provide therapeutic benefit. (see details here)
    • Market Capitalization: $326M
    • Pipeline: (see here)
      • Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Summary

The MunAiMarkets Ai-focused micro/small-cap clinical-stage drug discovery stocks portfolio went DOWN 9.6% w/e November 15th and is now DOWN 45.2% YTD.